

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051301 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number: PCT/US02/39890
(22) International Filing Date:
13 December 2002 (13.12.2002)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/339,390 14 December 2001 (14.12.2001) US

(71) Applicant (*for all designated States except US*): **HEMI-SPHERX BIOPHARMA** [US/US]: One Penn Center, 1617 JFK Boulevard, Philadelphia, PA 19103 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CARTER, William, A.** [US/US]; 8 Cooks Glen Road, Spring City, PA 19475 (US). **STRAYER, David, R.** [US/US]; 918 Rock Creek road, Bryn Mawr, PA 19010 (US).

(74) Agent: **CRAWFORD, Arthur, R.**; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY

(57) Abstract: In the treatment of HIV administration of dsRNA at an appropriate stage in highly active antiretroviral (HAART) therapy of HIV allows for the discontinuation of HAART by increasing the time to HIV rebound after stopping HAART.

WO 03/051301 A2